Weight gain in females with a diagnosis of breast cancer by Therrien, Sheryl
UNLV Retrospective Theses & Dissertations 
1-1-1993 
Weight gain in females with a diagnosis of breast cancer 
Sheryl Therrien 
University of Nevada, Las Vegas 
Follow this and additional works at: https://digitalscholarship.unlv.edu/rtds 
Repository Citation 
Therrien, Sheryl, "Weight gain in females with a diagnosis of breast cancer" (1993). UNLV Retrospective 
Theses & Dissertations. 273. 
https://digitalscholarship.unlv.edu/rtds/273 
This Thesis is protected by copyright and/or related rights. It has been brought to you by Digital Scholarship@UNLV 
with permission from the rights-holder(s). You are free to use this Thesis in any way that is permitted by the 
copyright and related rights legislation that applies to your use. For other uses you need to obtain permission from 
the rights-holder(s) directly, unless additional rights are indicated by a Creative Commons license in the record and/
or on the work itself. 
 
This Thesis has been accepted for inclusion in UNLV Retrospective Theses & Dissertations by an authorized 
administrator of Digital Scholarship@UNLV. For more information, please contact digitalscholarship@unlv.edu. 
INFORMATION TO USERS
This manuscript has been reproduced from the microfilm master. UMI 
films the text directly from the original or copy submitted. Thus, some 
thesis and dissertation copies are in typewriter face, while others may 
be from any type of computer printer.
The quality of this reproduction is dependent upon the quality of the 
copy submitted. Broken or indistinct print, colored or poor quality 
illustrations and photographs, print bleedthrough, substandard margins, 
and improper alignment can adversely affect reproduction.
In the unlikely event that the author did not send UMI a complete 
manuscript and there are missing pages, these will be noted. Also, if 
unauthorized copyright material had to be removed, a note will indicate 
the deletion.
Oversize materials (e.g., maps, drawings, charts) are reproduced by 
sectioning the original, beginning at the upper left-hand corner and 
continuing from left to right in equal sections with small overlaps. Each 
original is also photographed in one exposure and is included in 
reduced form at the back of the book.
Photographs included in the original manuscript have been reproduced 
xerographically in this copy. Higher quality 6" x 9" black and white 
photographic prints are available for any photographs or illustrations 
appearing in this copy for an additional charge. Contact UMI directly 
to order.
University Microfilms In ternational 
A Bell & Howell Inform ation C o m p an y  
3 0 0  North Z e e b  R oad . Ann Arbor. Ml 48106-1346  USA 
313 /7 6 1 -4 7 0 0  8 0 0 /5 2 1 -0 6 0 0

Order Num ber 1352567
Weight gain in females w ith  a diagnosis o f breast cancer
Therrien, Sheryl, M.S.N.
University of Nevada, Las Vegas, 1993
Copyright © 1993 by Therrien, Sheryl. All rights reserved.
UMI
300 N. Zeeb Rd.
Ann Arbor, MI 48106

Weight Gain in Females With a Diagnosis 
of Breast Cancer
by
Sheryl Therrien
A thesis submitted in partial fulfillment 
of the requirements for the degree of
Master of Science 
in 
Nursing 
Department of Nursing 
University of Nevada, Las Vegas
May 1993
1993 Sheryl Therrien 
All Rights Reserved
The thesis of Sheryl Therrien for the degree of Master of 
Science Nursing is approved.
Chairperson, Margaret Louis, Ph.D.
^  L)7TT___________________
Examining) Committee scomber, Rosemary Witt, Ph.D.
Examining Committee Member, Susan Michael, M.S.N.
Graduate Faculty Representative, Shirley Emerson, Ph.D.
Graduate Dean,Ronald Smith, Ph.D.
University of Nevada, Las Vegas 
May 1993
ii
A B STRACT
A retrospective longitudinal study was done on 213 
women with a diagnosis of breast cancer. The subjects' 
weights were tracked over one and two years after a 
diagnosis of stage I or stage II breast cancer. The 
subjects were identified from the medical records of the 
practices of two local Oncologists who agreed to participate 
in the study. The study tested the hypotheses: a.) Women
with stage I or stage II breast cancer gain weight, b.)
Women with stage I breast cancer gain more weight than women 
with stage II breast cancer, c.) Women with stage II breast 
cancer on adjuvant chemotherapy with Doxorubicin gain more 
weight than women with stage I or stage II breast cancer on 
Tamoxifen alone, and d.) Women with breast cancer who do 
gain weight do not lose the weight after chemotherapy 
treatment ends.
Findings failed to support null hypothesis in a and d, 
but b and c were retained. On the average women with a 
diagnosis of either stage I or stage II breast cancer did 
gain weight. By the end of twenty-four months women with 
stage I breast cancer on the average had gained more weight 
than women with stage II breast cancer but not at a 
statistically significant level. Women with stage II breast
cancer receiving adjuvant chemotherapy with Doxorubicin 
gained more weight than women who received Tamoxifen alone 
but not at a statistically significant level. At the 
twenty-four month mark women with stage II breast cancer had 
leveled off in weight gain but had not achieved their pre­
diagnosis weight and women with stage I breast cancer were 
apparently on an upward curve of weight gain. The findings 
suggest more investigation into the cause of the weight gain 
as well as further investigation into actual weight gain in 
this population.
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CHAPTER I
INTRODUCTION
In 1992 thirty two percent of cancer incidence in 
females was in the form of breast cancer. Breast cancer is 
the second cause of death from cancer in females, with the 
first cause being lung cancer. There will be 182,000 new 
cases of breast cancer diagnosed in women in 1993. The 
statistics published by the American Cancer Society (1992) 
indicated that one in nine females would be diagnosed with 
breast cancer during their life time. Statistics released 
at the 1992 Scripp's Oncology Conference suggest that this 
figure actually may be one in eight. These statistics 
suggest that breast cancer will impact nearly everyone at 
sometime in their life, if not with a personal experience 
then through a friend or relative.
In the past several years while working in an oncology 
practice, the researcher noted that a large number of 
patients with a diagnosis of breast cancer complained of 
gaining weight. In reviewing the literature, it was found a 
weight gain has been noted after diagnosis of breast cancer 
in females. In addition obesity and diets high in fat have 
been identified as risk factors for developing certain 
cancers such as breast and colon (Dollinger, Rosenbaum and
2Cable, 1991). However, the literature does not provide data 
on why there is a weight gain after a diagnosis and 
treatment of stage II breast cancer, and if a weight gain 
also occurs after a diagnosis of stage I cancer.
RATIONALE AND SIGNIFICANCE OF STUDY
Boyd, Campbell, Germanson, Thompson, Sutherland & 
Meakin (1981) found that body weight, especially obesity was 
"strongly associated with disease recurrence" in seven 
hundred forty-nine women with breast cancer in stages I, II 
and III. The study concluded that weight loss for obese 
breast cancer patients could reduce the risk of recurrence. 
In a 1980 study these same authors reached the conclusion 
that improved survival time might be had by encouraging 
over-weight women with a diagnosis of breast cancer to lose 
weight.
Zumoff, Gorzynski, Katz, Weiner, Levin, Holland & 
Fukushima (1982) in a longitudinal study over a ten year 
period found that twenty-five female breast cancer patients 
who were normally weighted survived while only thirty-one 
percent of the over-weight women were alive ten years after 
diagnosis. Newman, Miller and Howe (1986) in a study of 100 
newly diagnosed women matched with normal controls had 
similar findings.
3Wynder and Cohen (1982) wrote an editorial proposing a 
diet low in fat be used as an adjuvant therapy in breast 
cancer to decrease recurrence and increase survival time. 
Their premise being that a high fat diet leads to weight 
gain and obesity, whereas a low fat diet promotes weight 
stability or loss thus helping to maintain normal weight. 
Gregorio, Emrich, Graham, Marshall & Nemoto (1985) 
demonstrated a "1.4 fold increase in estimated death risk 
for each 1,000 grams of fat intake per month" (p = .02) in a 
population of 953 women with a diagnosis of breast cancer. 
The subjects were accumulated over an eight year period from 
1957 to 1965. The researchers then used data collected at 
the time of intake to time of death or last contact for this 
study. They observed an effect on survival time directly 
linked to dietary fat intake. Dietary fat intake also has a 
direct effect on body weight.
The literature has indicated that women with breast 
cancer do gain weight and that over-weight and obesity are 
poor prognostic indicators. The present longitudinal study 
will provide more detailed information as to when and in 
what stage women with a diagnosis of breast cancer gain 
weight.
4PROBLEM
The literature review suggests limited study of what 
happens to women's weight after a diagnosis of breast 
cancer. The nursing studies are mostly written in narrative 
or anecdotal style with little or no information on data 
collection or statistical procedures. The medical studies 
are usually on animal models. Ancillary studies from other 
disciplines are supportive but tend to be tangential, with 
few directed to the actual problem at hand.
Dixon, Moritz and Baker (1978) while looking at 
cachexia in cancer patients in general found that breast 
cancer patients appeared to gain weight. The authors 
reported the above results in an article as an "unexpected 
finding". Following this landmark article many studies on 
why women gain weight after diagnosis of breast cancer have 
been completed. The subsequent studies indicate findings 
supportive of the hypothesis of weight gain within the first 
six months to a year after diagnosis of stage II breast 
cancer and adjuvant chemotherapy.
The question that thus arises is whether there is 
weight gain in all women with a diagnosis of either stage I 
or stage II breast cancer or is weight gain only in women
experiencing adjuvant chemotherapy for stage II breast 
cancer? This study proposes to answer that question.
6CHAPTER II 
LITERATURE REVIEW
INTRODUCTION
In 1988, cancer was the second highest cause of death 
in all age groups, with heart disease being the highest 
according to the American Cancer Society (Boring, Squires & 
Tong, 1992). The American Cancer Society projected 
1,170,000 new cancer cases in 1993 with 526,000 deaths from 
cancer in that same time period. The incidence of cancer 
has increased by eleven percent in the last forty years.
This increase is mostly in highly industrialized nations, 
such as the United States. More than 5,000,000 Americans 
are cancer survivors and 3,000,000 of these are over the 
five year mark in survival time. In 1930, one person in 
thirty could expect to be diagnosed with cancer but by 1985 
three in eight persons could expect to develop cancer before 
they die. As these statistics indicate cancer has a vast 
effect on the population. Considering the impact of the 
cancer process anything that can be done to decrease 
incidence or prevent recurrence is important. The
7institution of a program of primary intervention could be 
beneficial in preventing both incidence or recurrence.
While the implications of the cancer process is too vast to 
study all at once, smaller problems may be studied to find 
the answers which will contribute to an overall knowledge
base. This study examines one of these smaller problems,
weight gain after diagnosis and treatment for breast cancer.
DIETARY FAT RISK
One of the first reports of the relationship of high 
fat diet and tumor growth was by Tannenbaum (1942). His 
study showed a positive correlation to dietary fat and 
cancer incidence. Following Tannenbaum's study there were 
several studies to confirm and verify his results. Many of 
these studies also found that there was a positive 
correlation between high dietary fat intake and obesity.
Abe, Kumagai, Kimura, Hirosaki & Nakamura (1976), Adami, 
Rimsten, Steinkuist & Vegelius (1977), Boyd, Campbell, 
Germanson, Thompson, Sutherland & Meakin (1980, 1981 &
1985), Brisson, Morrison, Kopans, Sadowsky, Kalisher, 
Twaddle, Meyer, Henschke & Cole (1984) and Carroll (1975), 
all found that obesity or body weight was a high risk factor 
for developing breast cancer. These investigators, plus 
multiple other studies, found that body weight is one of the 
risk factors in the development of breast cancer. Many
8investigators also found a positive correlation between 
dietary fat intake and weight gain.
In a longitudinal study, with data gathered over an 
eight year period, Willett, Hunter, Stampfer, Colditz, 
Manson, Spiegleman, Rosner, Hennekene & Speizer (1992) 
studied the connection between dietary fat intake and the 
incidence of breast cancer and found no relationship between 
the two variables. The population studied consisted of 
nurses, and the sample consisted of 121,700 females. The 
Willett, Hunter, Stampfer, Colditz, Manson, Spiegleman, 
Rosner, Hennekene & Speizer study found results which differ 
significantly from other research, but it may be premature 
to negate the findings of others. The write up of the 
findings leave several unanswered questions. First, since 
the subjects were nurses, were they more likely to eat a 
healthier diet than the normal population due to their 
knowledge from being in a health related profession? It was 
noted that only 1429 subjects were diagnosed with breast 
cancer, an incidence far below the statistical norm of one 
in nine. Second, in the presentation of the data the ages 
of the subjects was reported as a broad range, but the 
number of subjects which fell in each age range was not 
identified. Thus it is unknown how many subjects were in 
the older age range which is associated with an increased 
cancer risk. Third, the dietary fat intake was also 
reported as a wide range, but information as to how many
9subjects fell in each range was omitted. Last, the data for 
approximately 28% of the respondents was incomplete.
While one has to agree this is a significant study due 
to the large sample size and the time frame the subjects 
were followed; it would also be premature to allow this one 
study to negate the multiple other studies with contrary 
findings without further investigation and replication. 
Further studies should also address the deficiencies 
identified in the report of Willett, Hunter, Stampfer, 
Colditz, Manson, Spiegleman, Rosner, Hennekene & Speizer 
(1992) .
WEIGHT GAIN IN ADJUVANT THERAPY
DeGeorge (1989), in a study of seventy-three subjects, 
with stage II breast cancer, examined eating patterns and 
type of eating groups into which the subjects could be 
classified. DeGeorge found no significant difference 
between the eating groups, which were labeled inhibited 
(described as people who will gorge after being given a 
loading sample such as four ounces of ice cream) versus 
uninhibited (described as people who restrain their eating 
behavior after a loading sample such as four ounces of ice 
cream) eaters. DeGeorge also looked at different treatment 
modalities, i.e. Tamoxifen versus radiation versus 
chemotherapy in the stage II breast cancer patient to help
10
explain her findings. DeGeorge found no significant 
difference between the different groups in the study.
A weight gain in fifty to seventy five percent of women 
with stage II breast cancer on adjuvant therapy was found by 
Stevens and Gilmore (1986). They also found that post­
menopausal women were less likely to gain weight than those 
who were pre- or peri-menopausal. These findings were the 
first to note a significant relationship between menopausal 
status and weight gain in subjects with a diagnosis of 
breast cancer. Based on the study findings the author 
included methods to prevent weight gain and gave 
practitioners direction in setting up primary and tertiary 
programs for the at risk population.
Huntington (1984) also found that about fifty percent 
of the twenty-nine subjects in his study gained weight and 
that pre- or peri-menopausal women were more likely to gain 
weight than post-menopausal women. This finding supports 
Stevens and Gilmore's findings and the findings of several 
other studies including Hernandez's 1983 study. However, 
there are gaps as to how Huntington reached his conclusion 
that weight gain was due to decreased activity in this 
population of women and seemed to be based on conjecture. 
Since Huntington presented no evidence to support his 
conclusion, logic indicates that all groups with decreased 
activity should gain weight.
Foltz (1984) examined the relationship between weight 
gain in women on adjuvant chemotherapy for stage II breast
11
cancer and five factors. These five factors were: 
activity, depression, intake, serum estradiol level and 
metabolic rate. Foltz found that four of the factors had no 
influence on the weight gain and could not identify a reason 
why the fifth, lower estradiol level, was positively 
correlated with weight gain. The above finding did not add 
to explaining lower weight gain among post-menopausal women 
with stage II breast cancer, than pre- or peri-menopausal 
women with the same disease.
Cruz, Muss, Brockschmidt & Evans (1990) found a 
significant weight gain in women with metastatic breast 
cancer who were given Megace. This finding is not 
surprising, since a well documented side effect of Megace is 
weight gain due to the drug's ability to increase appetite. 
Megace is often prescribed to help increase the appetite in 
cachectic cancer patients without a diagnosis of breast 
cancer.
Heasman, Sutherland, Campbell, Elhakim & Boyd (1985), 
studied two hundred thirty-seven women with stage II breast 
cancer on adjuvant chemotherapy and found that ninety-six 
percent gained weight during treatment and that none of the 
subjects lost weight. The subjects were followed for a 
period of at least twelve months. The researchers found no 
association between weight gain and whether the cancer 
recurred or not.
Goodwin, Panzarella & Boyd (1988) studied one hundred 
ninety-one women with stage II breast cancer on adjuvant
12
chemotherapy. A significant weight gain was noted in the 
study's sample, but the data did not support an association 
between weight gain and the treatment, nor was any 
prognostic value achieved by looking at women who gained 
weight over those who did not gain weight. Their rationale 
for not recommending further study was based on difficulties 
with data collection, reliability of data and their 
assumption that "weight gain during the first year" post 
breast cancer diagnosis appears to have no influence on 
"relapse or survival".
Whittenberg (1990) in writing about a study done in 
Canada reported a significant weight gain in women on 
adjuvant chemotherapy with stage II breast cancer. The 
reported weight gains were up to ten pounds per year after 
diagnosis. The study of the amount of weight gain had been 
ongoing for two years at the time of the report. The 
investigators were following weight change during adjuvant 
chemotherapy and after completion of chemotherapy to see if 
the subjects returned to pre-treatment weight. There was no 
report on whether the subjects returned to pre-treatment 
weight as the study was still in progress. These 
investigators also stated that a poorer prognosis was found 
among women who gained weight, than those who did not gain 
weight after a diagnosis of breast cancer. This finding 
suggested that further study be done to determine what are 
the detrimental prognostic factors.
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WEIGHT GAIN AND RISK OF RECURRENCE
Knobf, Mullen, Xistris & Moritz (1983) studied eighty- 
seven women with stage II breast cancer on adjuvant 
chemotherapy and found weight gain among the sample. The 
authors suggested that a significant weight gain might lead 
to a greater chance of disease recurrence. Many studies 
support the observation of a greater chance of disease 
recurrence in obese women.
Bonomi, Bunting, Fishman, Wolter, Hernandez, Foltz, 
Shorey, Strauss, Anderson, Roseman & Economou (1984) studied 
women with stage II breast cancer and weight gain during the 
length of disease free survival, that is time from remission 
to recurrence of the breast cancer. Their data suggested 
that weight gain during adjuvant therapy may be detrimental. 
This information was reported in an abstract. Thus from the 
minimal information published, the quality of the data or 
the methodology of the study can not be determined.
Levine (1990) studied 33 women on adjuvant chemotherapy 
and found sixty-four percent gained weight. The author 
found that the women who gained weight showed more 
psychological stress and had a poorer self image, than those 
who did not gain weight. This finding supports the theory 
that stressors which impact what Neuman (1989) describes as
14
the flexible lines of defense and resistance as well as the 
lines of defense, impact the system leading to 
symptomatology. Levine's sample only included women with 
stage II breast cancer on chemotherapy. This raises the 
question if stage I patients perceive less psychological 
stress or have a better self image than stage II patients. 
Another factor could be that stage I patients know they have 
a better long term prognosis than stage II patients. 
Unfortunately this question remains to be answered.
Camoriano, Loprinzi, Ingle, Therneau, Krook & Veeder 
(1990) studied five hundred forty-five breast cancer 
subjects for a period of sixty weeks. The subjects had 
stage II breast cancer and were on adjuvant therapy study. 
The authors found that women who gained more than the median 
weight gain (5.9 kilograms in pre-menopausal subjects and 
3.6 kilograms in post-menopausal subjects) had one and one 
half greater relapse rate than women who were at or below 
the median total weight of 64.8 kilograms. The authors 
concluded that weight gain increased the chance of relapse 
and death.
In a study of sixty-one women with stage II breast 
cancer on adjuvant chemotherapy Hernandez, Bonomi, Hoeltgen, 
Roseman, Slayton, Wolter & Foltz (1983) reported on the 
adverse prognostic effects of obesity and weight gain. No 
overt relationships were found between weight gain and 
several variables, including menopausal status and the fact 
that the subjects were on Tamoxifen.
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WEIGHT LOSS
Rowland-Payne, Abbott, Jones, Powles & Coombes (1982) 
found a significant weight loss in women with advanced 
metastatic breast cancer. They studied sixty-two subjects 
for sixteen months who were on adjuvant chemotherapy. Their 
subjects lost an average of five kilograms during therapy. 
This was the only study found where a weight loss was found 
in women with stage II breast cancer who were on adjuvant 
chemotherapy. Data related to how advanced these stage II 
subjects were and estrogen and progesterone status was not 
reported. DNA phase, ploidy and number of positive lymph 
nodes were not included. The authors were not looking for a 
weight gain and there was no discussion as to why the 
findings in this study are in opposition to all of the other 
studies reviewed.
SUMMARY
A plethora of studies exist demonstrating a connection 
between weight gain and the diagnosis of stage II breast 
cancer. The weight gain appears to be a well established 
fact, but there is little explanation as to the cause of the
16
weight gain. Many women with stage I breast cancer also 
complain of gaining weight but few in depth studies have 
been related to this stage of the disease or the complaint 
of weight gain by this group. If both stage I and stage II 
breast cancer category women gain weight then the 
commonalties between the groups could be explored, rather 
than looking at treatment modes for the cause of weight 
gain. Since several investigators have noted a poorer 
prognostic outcome in overweight women, the ability to 
identify causative factors for this weight gain, would be 
beneficial to this population of patients. For example, a 
primary intervention teaching program could be developed to 
help women diagnosed with breast cancer avoid the weight 
gain thus increasing their chance of disease free survival 
and reducing the chance of disease recurrence.
THEORETICAL FRAMEWORK
This study uses Betty Neuman's (1989) theoretical 
framework as a guide. Neuman's theory, a systems model, 
provides the outline and methods utilized in this study.
The framework also provides guidance on data collection, 
analysis, interpretation of the findings and suggestions for 
future study. The Neuman model can be used with groups or 
individuals and provides insights into several categories of
17
practice. The model can guide patient care and curriculum 
as well as research.
Neuman's conceptualization includes the idea of a basic 
core structure which is the elemental life force of an 
entity. The core is seen as necessary for survival and is 
also what makes the entity a unique being. The entity has 
an outer ring which is called the flexible line of defense 
and normally protects the entity from stressors. The 
flexible line of defense varies in response, according to 
where the entity is on the wellness continuum. If a 
stressor penetrates the flexible line of defense the entity 
will demonstrate signs of disease and may become ill.
Neuman also conceptualizes a normal line of defense 
inside the flexible line of defense which represents the 
entity as it is at present. This normal line of defense 
represents such things as coping mechanisms, and support 
systems which the entity can mobilize to defend against 
stressors penetrating the flexible lines of defense. If the 
line of defense is penetrated the entity becomes ill and 
requires intervention to rebuild the line of defense.
The lines of resistance are the entity's coping mechanisms 
to fight off the disease or illness, for example the immune 
system. If the stressor continues and penetrates the lines 
of resistance the entity's very existence is threatened. If 
the stressors penetrate to the basic core structure death is 
frequently the outcome.
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Neuman defines primary prevention as actions designed 
to keep the flexible line of defense intact and 
interventions to strengthen these lines. Secondary 
prevention is care after the flexible lines of defense have 
been penetrated and signs of disease and/or illness are 
present. Tertiary prevention is defined as help in 
rebuilding the line of defense and/or the lines of 
resistance after penetration. Tertiary prevention is 
assistance to help the entity regain its former state of 
wellness.
Stressors are defined as anything which attacks the 
flexible lines of defense, the line of defense or the lines 
of resistance. Stressors may be either positive or negative 
events. Stressors come in five categories: physical,
psychological, social, developmental or spiritual. They can 
be interpersonal, intrapersonal or extrapersonal. This 
study will be dealing with all three categories of 
prevention. By virtue of being diagnosed with breast cancer 
it can be assumed that the lines of defense have been 
penetrated. The secondary prevention is related to the type 
of treatment they receive for the cancer process. Tertiary 
prevention is related to assisting the patients to regain 
their previous wellness and life-style. Primary prevention 
could include setting up a program to help prevent weight 
gain and therefore reduce the chances of recurrent disease.
Some identified stressors include the diagnosis of 
cancer, surgery, possible radiation, staging work-up,
19
chemotherapy and possible hormonal therapy. These stressors 
may be categorized as physical, psychological, social, 
developmental and spiritual in nature. The flexible lines 
of defense and the normal lines of defense have been broken. 
Secondary prevention is required to assist with repair of 
the lines. This study will help clarify the stressors and 
the response to the stressors. Suggestions for primary and 
tertiary prevention programs should arise from the results 
of this study. The main stressor considered in this study 
will be the incidence of weight gain as an additional 
stressor with the diagnosis of breast cancer.
This study address some of the concerns presented in a 
letter to the editor regarding the Dixon, Moritz & Baker
(1978) article. Harris (1979) addressed concerns of a mixed 
population, a small sample size, unreported disease stage 
and menopausal status. The population of the study in 
question included several different types of cancer 
patients, including colon, lung and bladder. The total 
number of subjects in the Dixon, Moritz and Baker study was 
ninety-eight and of this thirty-two were breast cancer 
patients. The disease stage of the breast cancer patients 
was not given nor was the menopausal status. Both the stage 
and menopausal status have effected the results obtained and 
Harris raised questions about these unaddressed factors.
The present study attempted to address these concerns.
20
HYPOTHESIS
The research hypotheses for this study are:
1. Women with stage I or stage II breast cancer gain 
weight.
2. Women with stage I breast cancer gain more weight 
than women with stage II breast cancer.
3. Women with stage II breast cancer on adjuvant 
chemotherapy with Doxorubicin gain more weight than women 
with stage I or stage II breast cancer on Tamoxifen alone.
4. Women with breast cancer who gain weight do not lose 
that weight after treatment ends.
DEFINITION OF TERMS
Weight Gain - after the first recorded office visit any 
gain, over the mean body weight.
Weight loss - after the first recorded office visit, any 
loss under the mean body weight.
Stage I disease - tumor confined to the affected breast with 
no positive axillary lymph nodes or distant metastasis, 
three centimeters or less in size.
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Stage II disease - Tumor in the affected breast with 
positive axillary lymph nodes and no other local or distant 
metastasis.
Adjuvant therapy - Chemotherapy given in stage II disease to 
prevent recurrence when surgery was effective. These 
include 5-Flurouracil, Methotrexate, Doxorubicin, Cytoxan 
and Tamoxifen. Women in a clinical trial utilizing any 
other drugs except those listed will be excluded.
Local therapy - surgery and radiation given after lumpectomy 
(these are mutually inclusive), or surgery such as a simple 
mastectomy, modified radical mastectomy or a Halsted radical 
mastectomy or radiation to the chest wall.
Systemic therapy - chemotherapy or hormonal therapy given by 
oral, intermuscular or intravenous route.
Tamoxifen alone - Tamoxifen is the only systemic therapy 
given. There is no other oral, intermuscular or intravenous 
chemotherapy given.
T, N,M staging method - Universal method of staging cancer by 
tumor size, nodal involvement and presence or absence of 
distant metastases (Appendix F).
CHAPTER III
METHODOLOGY
DESIGN
This study is a retrospective longitudinal study of 
women with a diagnosis of breast cancer, either stage I or 
stage II disease. Women in more advanced stages of the 
disease were not studied. The stage of disease was 
determined by the T,N,M staging method, which is a universal 
method of staging cancer by tumor size, nodal involvement 
and presence or absence of distant metastases (Appendix F), 
using data at the time of diagnosis, or as designated on the 
pathology report if T,N,M information was lacking.
Previous studies such as Dixon, Moritz & Baker (1978) 
have been criticized by Harris (1979) concerning the use of 
mixed diagnosis and stage of disease. The methodology for 
the present study addresses those concerns.
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POPULATION AND SAMPLE
The subjects were all female patients diagnosed as 
having stage I or II breast cancer. The subjects were all 
patients of two private oncology practices located in a 
large southwestern city. Data were collected by reviewing 
medical records of eligible subjects, those diagnosed with 
either stage I or stage II breast cancer, prior to l 
September 1991. The date of diagnosis on one subject, the 
earliest sampled, was 1972. Women with stage II disease 
were eligible if they received 5-Flurouracil, Methotrexate, 
Doxorubicin, Cytoxan or Tamoxifen singly or in any 
combination. Subjects were ineligible for inclusion if the 
medical record indicated they were participants in clinical 
trials including any other chemotherapeudic drug except 
those listed. All data were collected from the subject's 
medical record.
PROCEDURE
It is the practice of both offices to weigh patients on 
every office visit. Thus weight changes from first visit to 
most recent visit were available. It is assumed that the
24
patient's weight was always taken on the same scale. The 
scales, one in each office, are a balance beam type 
calibrated every six months by Associated Pathologists 
Biomedical Department, a firm licensed to certify the 
accuracy of the instrument. In each office a Registered 
Nurse weighed the patient and recorded the weight on a flow 
sheet. The flow sheet was used for all patients whether or 
not they received chemotherapy. The flow sheet recorded the 
patients height, weight, vital signs, laboratory test 
results and pertinent telephone conversation notes between 
office visits. The first office visit weight was used as 
the baseline weight since pre-diagnosis and/or pre-operative 
weight was not consistently available in the patient medical 
record. Other data came from laboratory records and 
operative records on the patient found in the patient 
medical record.
All female patients with a diagnosis of stage I or stage II 
breast cancer were eligible, if at least one year had 
elapsed since diagnosis so that weight trend data were 
available. In chemotherapy protocols the drugs are given 
for a minimum of six months to a maximum of twelve months 
and Tamoxifen is given for three to five years. It was 
determined that patients with less than one year elapsed 
time since diagnosis had insufficient data to identify a 
trend toward weight gain or loss. The use of the medical 
records of patients diagnosed prior to l September 1991 
assured that one year elapsed since diagnosis. All
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available eligible medical records from both medical 
practice sites were reviewed. This sampling technique 
provided a sufficient number of subject medical records, to 
address Harris's (1979) concern with sample size. The data 
collection procedure contained several steps. First, the 
medical records clerk in each office pulled all medical 
records of patients with a diagnosis of breast cancer. 
Second, the data collection team, consisted of Registered 
Nurses from each medical office. Then the medical record 
was checked for the date of diagnosis. Third the data 
collection team checked each medical record for treatment 
type and chemotherapy drugs used. The collector rejected 
any medical record that indicated that the patient had been 
prescribed any drug not within the inclusion criteria.
Chemotherapy protocols have remained relatively stable 
over the past five years in the most common protocols for 
breast cancer, one drug Methotrexate has been changed to 
Doxorubicin. This change was made about three years ago 
based on the recommendation of the National Cancer Institute 
following multiple studies. This change should not impact 
the focus of this study, weight gain, since the side effects 
of the combination of the chemotherapy agents are basically 
the same. The only different side effect is that 
Doxorubicin is an extravasator which can cause a burn if it 
is not given in the vein. The difference between the change 
from Methotrexate to Doxorubicin was noted in the data 
collection process and testing was done to assure equality.
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ASSUMPTIONS
Several assumptions were make regarding the data 
collection and medical records. Since only a Registered 
Nurse, in each office, weighed the patient and recorded the 
information, it was assumed that the information was 
recorded accurately. It was also assumed that the nurse 
accurately weighed the patient even though there probably 
had been a series of nurses in each office. It was assumed 
patients provided an accurate pregnancy and family history 
because of the seriousness of the disease and the importance 
of accurate health history information.
DATA COLLECTION
The data were collected over a period of four weeks.
A team of data collectors was instructed how to collect the 
data and what information was needed. A training session 
with each person was done prior to actual data collection. 
Each individual reviewed charts and had the results verified 
by the researcher to be sure the data were collected 
uniformly.
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Demographic data were obtained from each subject's 
chart including age. The data on age of the subjects were 
collected and a mean age calculated to address Harris's
(1979) concern, with mean age calculated from the mean year 
of birth of all subjects and common age of the at risk 
population. Harris felt that the explanation of the weight 
gain might be menopausal status. Other data collected 
included: menopausal status; type of surgery; receptor
status; DNA information; type of treatment; number of 
pregnancies; length of time since diagnosis; recurrence; 
site of original tumor; size of original tumor; and family 
history of breast cancer.
28
CHAPTER IV 
FINDINGS
The medical records of all the female breast cancer 
patients from two oncology practices served as the source of 
data. All medical records meeting eligibility requirements 
were included in the study thus providing 214 eligible 
records. Of the 214 medical records reviewed, one was not 
eligible due to data collection error, thus leaving 213 
eligible subject medical records.
SAMPLE
The largest majority (85%) of the data were collected 
in the office of one practice, while the other oncology 
practice was the data collection site of 15%. This 
disparity was predicted at the onset of the study. The 
earliest year of diagnosis was 1972 and the latest was 1991 
with mean year of 1988. The subjects ranged in age from 31 
to 90 years old, with a mean age of 62 and a mean year of 
birth of 1931. The convenience sampling reflected a sample
29
which was 87% Caucasian. One would like a larger sample 
from other racial as well as socioeconomic groups to help 
round out the statistics and confirm the data. All subjects 
had insurance coverage for treatment. Consequently, it 
would be difficult to project the results of this study to 
the total population of women with breast cancer. A sample 
of 213 subjects is a good sample size but still small in 
view of the size of the effected population. Because the 
sample was all female, the less than one percent of the male 
population effected by breast cancer can not be considered. 
Approximately fifty-one percent of the subjects had stage I 
disease and approximately forty-nine percent had stage II 
disease. Treatment start dates for stage II disease ranged 
from 1978 to 1992 with the mean year of 1988. One hundred 
thirty-three subjects were still on active treatment at the 
time of data collection. Active treatment was noted when 
women had radiation prior to starting their chemotherapy 
protocol, had elected to wait to start their chemotherapy 
until completely surgically healed and those women who are 
on Tamoxifen which they take for a minimum of three years. 
One hundred twenty-seven subjects were or had received 
Tamoxifen. Twenty-seven subjects had received Doxorubicin, 
Cytoxan and 5-Flurouracil while sixty-two subjects received 
Methotrexate, Cytoxan and 5-Flurouracil. There were only 
four subjects in this study who received Prednisone as part 
of their treatment and seven who received Megace as part of 
their treatment. Since all but one of these eleven subjects
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received either the Prednisone or Megace after the twenty- 
four month time frame when data were collected no separate 
analyses were done to exclude these subjects. One patient 
did receive Prednisone during the first twenty-four months 
post diagnosis as part of her treatment regime but it was 
felt that one subject would not skew the data so she was 
included in the final analysis. However, no conclusion can 
be made about the Prednisone impact on weight gain. Forty- 
one of the subjects had chest wall radiation of from 2500 to 
6400 Rads (radiation absorbed dose) .
Two of the subjects refused surgery beyond a fine 
needle biopsy, one hundred eighty-five had a modified 
radical mastectomy, twenty had a lumpectomy with axillary 
node dissection, four had a Halsted radical mastectomy and 
four had a simple mastectomy. The four subjects who had a 
simple mastectomy had pathologically proven intraductal 
disease only and simple mastectomy is considered the 
standard treatment for this population, which is diagnosed 
as stage I disease.
One hundred seventy subjects had been pregnant at least 
once. The number of pregnancies ranged from one to fifteen 
with a mean of 2.5 pregnancies per subject. Thirty-three 
subjects had never been pregnant and pregnancy information 
was missing on ten subjects. Age at first pregnancy ranged 
from 16 to 42 with a mean age at first pregnancy of 25.
A family history of at least one first degree relative 
with a diagnosis of breast cancer was found in 64 of the
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subjects. The information on family history of breast 
cancer was missing in nine of the subject charts. A 
breakdown of family history of breast cancer shows 19 had at 
least one sister, 21 had a mother, 2 had a daughter, 11 had 
a grandmother and 23 had at least one aunt with a history of 
breast cancer.
Breast involvement showed 103 subjects with just the 
left breast, 88 with the right breast, 19 had involvement of 
both breasts. For three subjects this information could not 
be found in the chart. The size of the primary tumor 
ranged from less than one centimeter to eleven centimeters 
with the mean size of 2.3 centimeters. Nodal involvement 
ranged from zero nodes to thirty-five nodes with the mean 
number of nodes being 2.8. Estrogen receptor test was 
positive for 150 subjects and 119 were progesterone receptor 
positive. DNA histogram information was collected when 
available but since this is a fairly new procedure only 
those subjects diagnosed since 1988 had this information and 
then not consistently until 1990. Aneuploid tumors were 
identified in 30 subjects, 4 had intermediate stage tumors 
and 55 had diploid tumors. Ploidy is a fairly new 
prognostic testing method where the pathologist looks at how 
the tumor cells appear. Diploid tumor cells appear nearly 
normal and are the best prognostic stage, intermediate look 
less normal and have a less favorable prognosis where 
aneuploid cells are the most abnormal looking cells and have 
the worst prognosis. In 21 subjects S-phase was high,
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intermediate in one subject and low in 38 subjects. Like 
the ploidy of the cells the number of cells in S-phase are 
prognostic with high S-phase being the ones with the worse 
prognosis. Menopausal status showed 45 pre-menopausal,
14 peri-menopausal and 137 post-menopausal with this 
information missing on 17 subjects. Menopausal status was 
collected with the demographic data from the chart by date 
of last menstrual period then applying the criteria outlined 
for menopausal status (definitions).
Recurrence of their tumor was noted for 39 subjects and 
17 were receiving treatment for the recurrence. These were 
subjects who had recurred at least twelve months after the 
original diagnosis so that this event did not influence the 
weights on which this study was focused.
HYPOTHESES TESTED
The Statistical Program for Social Sciences software 
was used to run all statistical analysis on the data 
collected.
The first null hypothesis tested was women with stage I 
or stage II breast cancer do not gain weight over a two year 
period post diagnosis.
The data showed a mean weight gain of approximately 
three pounds at the end of twelve months and four pounds by
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the end of twenty-four months. To test the null hypothesis 
MANOVAs with repeated measures were run (Stevens, 1992).
Two separate MANOVAs were run due to the fact that 
patients who were less than two years since diagnosis were 
included in the sample. One MANOVA was run including all 
weights, initial through twenty-four months, and another was 
run on weights initial through twelve months.
The MANOVA for repeated measures using initial weight 
through twenty-four months identified one hundred eleven 
subjects with complete data. The mean initial weight for 
this group was 148.7 pounds, and the mean weight at twenty- 
four months for this group was 154.7 pounds. This is a mean 
weight gain for this group of six pounds. The standard 
deviation ranged from 27.9 to 28.3 on the means of the six 
weight periods. There may have been some violation of 
sphericity but the Greenhouse-Geisser Epsilon (.67) showed 
this was within tolerances for multiple analysis rather than 
single analysis (Stevens, 1992). The overall Wilks was 
calculated for the twenty-four month time period.
Wilks = .7101, F= 8.814, df= 5,108, p= .000. The overall 
significant statistic allows rejection of the null 
hypothesis. To further analyze the data the mean weights 
were tested for difference by time periods. Helmert 
Contrasts (Stevens, 1992) show the mean weights that had 
changed from the initial weight were three months with 
F= 14.55, p= .000; six months with F= 14.64, p= .001; nine 
months with F= 11.49, p= .001; twelve months F= 12.087,
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Figure 1: Mean weight for subjects at only 12 (N = 161) and
24 months (N = ill)
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p= .001 and twenty-four months with F= 14.204, p= .000.
The MANOVA for repeated measures using initial weight 
through twelve months identified one hundred sixty-one 
subjects with complete data. The mean initial weight of 
this group was 150.5 pounds and the mean weight at twelve 
months was 154.5 pounds for a mean weight gain of four 
pounds. The sphericity of this sample was more nearly 
normal but may again have been violated. The Greenhouse- 
Geisser Epsilon was .67.
The MANOVA resulted in Wilks Lambda= .8268, F= 8.376, 
df = 4,160, p= .000. Again the Helmert Contrasts for this 
group showed the mean weight change at three months was 
significant with F= 16.307, p= .000; six months F= 18.13, 
p= .000; nine months F= 11.56, p= .001 and twelve months 
F= 10.416, p= .226. Consequently this null hypothesis is 
rejected and allows support that women with breast cancer of 
either stage I or stage II do gain weight at twelve and 
twenty-four months after diagnosis. The power of weight 
change by time ranged from a low of .90 to a high of .96.
The second null hypothesis tested was there is no 
difference in weight gain between women with stage I breast 
cancer and women with stage II breast cancer.
A MANOVA for repeated measures was run separating stage 
I from stage II subjects. For the twelve month period there 
was a total of 161 subjects, with 76 in the stage I group 
and 85 in the stage II group. Standard deviations for both 
groups were within a few tenths of each other, (stage I
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SD= 24.4 to 25.5 and stage II SD= 33.2 to 33.7). The 
results showed that over the first twelve months stage II 
subjects gained more weight than stage I subjects by a mean 
difference of about two pounds (figure 2). Stage I 
subjects' mean initial weight was 148.2 pounds and mean 
weight at the twelve months was 151.4 pounds which is a mean 
weight gain of 3.2 pounds. Stage II subjects' initial 
weight was 152.6 pounds and a mean weight at twelve months 
of 157.3 pounds or a mean weight gain of 4.7 pounds. The 
MANOVA of one hundred sixty-one subjects with twelve month 
data resulted in a Wilks= .82723, F= .22, DF = 1,109,
P= .64.
For the twenty-four month period a total of 111 
subjects with 60 in the stage I group and 51 in the stage II 
group. As with the 12 month group standard deviations were 
within a few tenths of each other ( stage I SD= 25.1 to 25.9 
and stage II SD= 30.6 to 31.7). Stage I subjects' mean 
initial weight was 150.2 pounds and the mean weight at the 
end of twenty-four months was 156.1 pounds which is a mean 
weight gain of approximately six pounds. Stage II subjects' 
mean initial weight was 147 pounds and the mean twenty-four 
months weight was 153.7 pounds with a mean weight gain of 
4.7 pounds (figure 3).
The MANOVA of the 111 subjects with twenty-four month 
data resulted in a Wilks= .956, F= .97, df= 5,107, p= .438, 
none of the weight by stage data was significant. Weight 
alone gave a Wilks= .714, F= 8.56, df= 5,107, p= .000. All
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Figure 2: Stage I (N = 76) versus stage II (N = 85)
subjects 12 month mean weight
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Figure 3: Stage I (N = 60) versus stage II (N = 51) 24
month mean weights
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weights were different with df= 1,111, p= .000 to .001. The 
power by stage was .046 at the highest level. Consequently 
the null hypothesis of no difference in weight gain between 
women with stage I and women with stage II breast cancer was 
retained.
The third null hypothesis tested stated that there will 
be no difference in weight gain between women with stage II 
breast cancer on adjuvant chemotherapy with Doxorubicin and 
women with stage I or stage II breast cancer on Tamoxifen 
alone.
A MANOVA for repeated measures was run on all subjects 
receiving chemotherapy for stage II breast cancer. Twenty- 
seven subjects receiving chemotherapy with Doxorubicin had a 
weight increase of six pounds over the twelve month time 
span. One hundred twenty-seven subjects who received 
Tamoxifen alone showed no greater weight gain than those who 
had not received Tamoxifen. The group who received 
Tamoxifen had an initial mean weight of 147 pounds and at 
twenty four months their mean weight was 153 pounds. The 
group who did not receive Tamoxifen had an initial mean 
weight of 151 pounds and their twenty-four month mean weight 
was 157 pounds (figure 4). Each group gained approximately 
six pounds. No statistical difference was found between the 
these groups F= .69, df= l 109, p= .406. Therefore the null 
hypothesis was retained.
The fourth null hypothesis tested was that women with
po
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Figure 4: chemotherapy with Doxorubicin (N = 27) versus
Tamoxifen (N = 127)
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breast cancer who gain weight will have no difference in 
weight from initial weight after treatment begins. A paired 
t-test for both the twelve and twenty-four month groups was 
run (Stevens, 1992).
Data for the twelve month group of 193 subjects found 
an initial mean weight of 149.35 pounds, SD= 30.49 and the 
twelve month mean weight of 153.29 pounds, SD= 31.05. The 
paired t-test analysis was t= -5.41. df= 192, two tailed 
p= .000. Data for the twenty-four month group of one 
hundred forty-six subjects was initial mean weight 149.11 
pounds, SD= 30.37 and the twenty-four month mean weight 
154.76, SD= 30.37. The paired t-test analysis was t= 6.48, 
df= 145, two tailed p= .000. A paired t-test was then done 
on one hundred thirty-four subjects comparing the twelve 
month weight with the twenty-four month weight. The twelve 
month mean weight was 151.05 pounds with SD= 28.92 and the 
twenty-four month mean weight was 153.12 pounds with 
SD= 28.97. The t= -3.37, df= 133 and the two tailed 
p= .001. Thus the null hypothesis was rejected.
In summary null hypothesis one and four were rejected 
and two and three were retained.
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CHAPTER V 
RESULTS
DISCUSSION
The purpose of this study was to test four null 
hypotheses. The first and fourth null hypotheses were not 
supported. The second and third were retained.
The first null hypothesis was women with stage I or 
stage II breast cancer do not gain weight. The data show 
that they do gain weight at a statistically significant 
level. Therefore the null hypothesis is rejected allowing 
support of the hypothesis that women with breast cancer gain 
weight through the twenty-four month period. This supports 
findings by Dixon, Moritz & Baker (1978), Stevens and 
Gilmore (1986), Goodwin, Panzarella and Boyd (1988),
Heasman, Sutherland, Campbell, Elhakim & Boyd (1985), Knobf, 
(1985), and Huntington (1984). This study included stage I 
subjects as a comparison looking for diagnosis or disease 
process as a possible answer to the weight gain versus 
treatment medications.
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To further determine weight gain relationship the 
second null hypothesis, there is no difference in weight 
gain between women with stage I and women with stage II 
breast cancer, was tested. This hypothesis was retained for 
the first twelve month period as both gained weight. Women 
with stage I breast cancer catch up and surpass the stage II 
women in weight gain by the end of twenty-four months and 
appear to be on an upward course (figure 2, chapter 4).
Since the literature on weight gain in stage I women with 
breast cancer is sparse there was no literature found to 
support this finding. Dixon, Moritz & Baker (1975) reported 
weight gain as an ancillary finding in her study and is the 
only study where early disease is mentioned. Early disease 
is presumed to mean stage I by context though it is not 
specifically stated. The finding that stage II women gain 
weight supports the information found in the literature, 
such as Heasman, Sutherland, Campbell, Elhakim & Boyd 
(1985), Huntington, (1985), Stevens and Gilmore, (1986) and 
Goodwin, Panzarella and Boyd, (1988) .
The third null hypothesis was, there is no difference 
in weight gain between women with stage II breast cancer on 
chemotherapy with Doxorubicin and women with stage I or 
stage II breast cancer who are given Tamoxifen alone. The 
null hypothesis was retained. However the data show that 
women receiving chemotherapy with Doxorubicin gain more 
weight than those on Tamoxifen alone but not a statistically 
significant level..
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Knobf (1985) observed an average weight gain of four 
pounds in women on Cytoxan, 5-Flurouracil and Methotrexate. 
Heasman et al (1985) found a mean weight gain of 4.3 
kilograms in 237 subjects on Cytoxan, 5-Fluouracil and 
Methotrexate. Goodwin, Panzarella and Boyd (1988) found 
that women on Cytoxan, 5-Fluouracil and Methotrexate gained 
weight, did not lose the weight and that there was no effect 
on prognosis due to the weight gain. The were no studies 
found on the effect of Doxorubicin, Cytoxan and '5- 
Flurouracil and weight gain.
This study suggests weight gain by both groups of study 
subjects is not different. This was an unexpected finding 
since one of the side effects of chemotherapy is a 
significant amount of nausea.
The fourth null hypothesis was women with a diagnosis 
of breast cancer will have no difference in weight from 
initial weight after treatment ends. The findings supported 
rejecting the null hypothesis. Stage I breast cancer 
patients show a continual weight gain through twenty-four 
months while stage II breast cancer patients appear to have 
leveled off in their weight gain sometime before twenty-four 
months (figure 2, chapter 4).
Two studies found in the literature Heasman,
Sutherland, Campbell, Elhakim & Boyd (1985) and Goodwin, 
Panzarella and Boyd (1988) support this finding. Both of 
these studies found a weight gain in women with breast 
cancer on adjuvant chemotherapy and both studies found that
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the weight was not lost at the end of the chemotherapy 
treatments.
THEORETICAL FRAMEWORK
The Neuman Systems Model (1989) identifies five 
variables comprising the system of the client entity. All 
five variables impact on the system and affect the system. 
The five variables are defined as physiological, 
psychological, sociocultural, developmental and spiritual. 
Stressors and stressor responses can be from any or all of 
the five variables. The physiological variable is probably 
the one variable most addressed by this study. The stressor 
is a diagnosis of breast cancer to which the system 
responds. Both the lines of defense and the flexible lines 
of defense are breached as are the lines of resistance.
Body structure and function are compromised by surgery which 
is disfiguring even if only a lumpectomy is done. Following 
surgery the woman is attempting to rebuild her lines of 
resistance, lines of defense and flexible lines of defense 
while at the same time those same lines are being breached 
by the post-surgical treatment itself.
The weight gain identified in this study and others may 
be the attempt to return to wellness. The fact that there 
is a weight gain suggests that there is a physiological 
response to a stressor. Neuman's Model predicts and
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explains the response to a stressor in the system as action 
attempting to rebuild the flexible lines of defense.
Neuman's sociocultural and developmental variables 
while not a focus of this study were in the demographic data 
collected. Sociocultural variables were limited in that the 
majority of subjects were white and all had insurance 
coverage. The developmental variable as age and menopausal 
status data were collected. This study did not address the 
significance of this data but plans are to address it in a 
future study. The psychological and spiritual variables 
were not included in this study as these variables were not 
pre-identified as impacting nor answering the questions 
raised by the hypotheses.
While this study mainly focused on the physiological 
variable of weight gain in women who are diagnosed with 
breast cancer. The four variables not addressed by the 
present study certainly will guide the direction of future 
studies designed to determine why the weight gain occurs.
As one can see Neuman explains possible factors for the 
physiological response of the weight gain found in this 
study and gives direction to future study as to why this 
population gains weight.
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LIMITATIONS
This study had several limitations such as: a sample
of convenience, some missing weight data, a racially biased 
subject population and not a long enough time span over 
which data were collected. It would perhaps have been 
better to collect data for five years after the initial 
visit than just twenty-four months to plot a more 
comprehensive trend in the weight change over time.
The mean age of the group was 61 years with 64% of the 
subjects falling in the post-menopausal group. Harris's 
(1978) concern that the weight gain Dixon, Moritz & Baker 
(1978) noted may have been due to menopausal status rather 
than disease is a valid concern. Data for this study was 
collected to address this concern. Possible explanations 
will be addressed in a later study since the current study 
focused only on whether there was or was not an actual 
weight gain.
CONCLUSIONS
Women in this study diagnosed with breast cancer did 
gain weight. Women with stage I breast cancer took longer
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to gain the weight but the study indicated that the weight 
gain was on an upward swing at twenty four months while 
stage II women appeared to level off somewhere between the 
twelve month and twenty-four month time frame. Women with 
stage I breast cancer had a mean initial weight 
approximately four pounds less (148.2) than women with stage 
II breast cancer (152.6). This is an interesting finding 
and should be studied in more depth in the future. Since 
both groups gained approximately six pounds this difference 
in initial weight may have no significance at all. The 
interesting factor here is the apparent catching up in 
weight and even surpassing the stage II subjects by the 
stage I subjects at the twenty-four month mark. Having a 
diagnosis of breast cancer with the response of a weight 
gain suggests this is a stressor which affects the flexible 
line of defense causing a reaction in the system evidenced 
by weight gain. This also suggests that the stressor may be 
the disease process rather than the treatment itself since 
stage I women who did not receive chemotherapy or hormonal 
therapy also gained weight.
Neuman model variables like developmental, age and 
menopausal status, may help explain the reason for the 
weight gain. The spiritual variable to which self image, 
support structure and belief systems belong also may give us 
clues as to where to look for the reason for the weight 
gain.
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This study supported the findings in the literature of 
weight gain among women with stage II breast cancer on 
adjuvant chemotherapy. Interestingly those women treated 
with Doxorubicin, the one chemotherapeutic drug which causes 
the most nausea, gained the most weight in the chemotherapy 
group. This study did not find a greater weight gain in 
women on Tamoxifen contrary to what was expected from the 
literature and drug side effect information listed in the 
drug information insert and literature produced by the 
pharmaceutical manufacturer.
With the twenty-four month time line allowed in this 
study, the researcher was unable to observe if there was a 
loss of weight after treatment, with the subject returning 
to baseline or initial weight. In fact the stage I group 
appear to continue to gain weight at this time marker. The 
appearance of a leveling out sometime after the twelfth 
month by stage II women could be related to recurrence and 
that we start losing them to their disease at this point. 
Further study is needed to confirm this however.
The statistical significance of the weight gain in 
women with both stage I and stage II breast cancer warrants 
further study. Future study should include a more randomly 
selected sample more fully representing the general 
population of women diagnosed with breast cancer. Future 
samples should include both a larger number of subjects of 
ethnic and racial backgrounds. Subjects in socioeconomic 
groups who do not have a insurance would also answer some of
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the questions both raised and left unanswered by the present 
study.
The weight gain could be considered a response to a 
stressor and identification of the stressor would be 
instrumental in developing an alternate response to the 
stressor. Some possibilities suggested by observation, 
literature review, interaction and interviews with women 
diagnosed with breast cancer are a perception of lack of 
self image, food as a defense mechanism, a spiritual 
response and in the case of those women on Doxorubicin, is 
it an attempt to curb the nausea? Some patients say they 
eat so they do not get that "queasy" feeling. This may be 
the normal line of defense responding to the "queasy" 
stressor.
Even though there was no statistical difference between 
the weight gain of women with stage I and stage II breast 
cancer the data are very interesting and should be studied 
further over a longer time frame. This particular group of 
subjects could be followed over the next five to ten years.
A longitudinal study might answer the unanswered questions 
related to return to pre-diagnosis weight and also show if 
the apparent upward trend of weight gain in stage I women 
continues over time or levels off as apparently occurs in 
stage II women. It also might show if the leveling off of 
stage II women is due to recurrence and disease process.
RECOMMENDATIONS
Suggestions for future study include: continue to 
follow this particular subject group over the next several 
years, start a study with a new group of subjects and follow 
them for the next five to ten years, attempt to define what 
the stressors are so a plan to assist these women in coping 
with the stressors can be found.
Look to each of Neumans' five variables for explanation 
of the weight gain by stressor identification and for 
assistance to help women with breast cancer cope with the 
diagnosis in a form other than eating.
While this information gathering proceeds health 
professionals can begin to educate this population of women 
that a weight gain occurs and provide information on weight 
control. A self help group could be set up through the 
Mastectomy Society. As for the actual study group of 
subjects we have already begun an educational program. Each 
of the women, seen by either of the physicians whose case 
load was used for this study, with a diagnosis of either 
stage I or stage II breast cancer is informed of this 
study's findings and a packet of information is given out. 
This packet includes information on nutrition, antiemetics 
and nausea prevention and exercise. Both physicians are
52
prescribing increased doses of antiemetics and allow their 
patients to follow a good commercial diet program if the 
patient so requests.
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Table l
Height in inches for all subjects
HEIGHT FREQUENCY PERCENT
53 l .5
57 1 . 5
59 3 1.4
60 13 6.1
61 16 7.5
62 33 15.5
63 28 13.1
64 28 13 .1
65 28 13.1
66 18 8.5
67 20 9.4
68 11 5.2
69 4 1.9
70 3 1.4
missing 6 2.8
213 100
Mean = 63.8
SD = 2.6
N = 207
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Table 2
Weight at time of first office visit for all subjects
WEIGHT IN POUNDS FREQUENCY PERCENT
<100 2 1
100 - 110 12 5.1
111 - 120 14
GO
121 - 130 20 9.4
131 - 140 32 15.1
141 - 150 46 22.2
151 - 160 22 10.4
161 - 170 18 8.4
171 - 180 15 7.1
181 - 190 5 2.4
191 - 200 7 3.3
201 - 210 4 1.9
211 - 220 3 1.4
221 - 230 3 1.4
231 - 240 3 1.4
241 - 250 3 1.4
251 - 260 1 . 5
210 100
Mean = 150.9
SD = 31.2
N = 213
7b
Table 3
Weight at three months for all subjects
WEIGHT IN POUNDS FREQUENCY PERCENT
<100 1 0.5
100-110 11 5.7
111-120 11 5.7
121-130 22 11.4
131-140 28 14.5
141-150 32 16.6
151-160 27 14
161-170 22 11.4
171-180 17 8.8
181-190 5 2.6
191-200 2 1.0
201-210 4 2.1
211-220 1 0.5
221-230 4 2.1
231-240 3 1.5
241-250 2 1.1
251-260 1 0.5
missing 20
213 100
Mean = 151.3
SD = 30.1
N = 193
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Table 4
Weight at six months for all subjects
WEIGHT IN POUNDS FREQUENCY PERCENT
<100 2 1.0
100-110 10 5 . 0
111-120 9 4.5
121-130 25 12.5
131-140 31 15.5
141-150 28 14.0
151-160 26 13 . 0
161-170 21 10.5
171-180 24 12 . 0
181-190 4 2.0
191-200 5 2.5
201-210 4 2.0
211-220 2 1.0
221-230 2 1.0
231-240 3 1.5
241-250 3 1.5
251-260 1 0.5
missing 13
213 100
Mean = 152.4
SD = 30.4
N = 200
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Table 5
Weight at nine months for all subjects
WEIGHT IN POUNDS FREQUENCY PERCENT
<100 3 1.6
100-110 6 3.3
111-120 8 4.9
121-130 20 12.8
131-140 27 14.6
141-150 33 17.8
151-160 21 11.4
161-170 14 8.1
171-180 25 13.0
181-190 7 3.7
191-200 2 1.1
201-210 7 3.8
211-220 2 1.1
221-230 0 .0
231-240 5 2 . 7
241-250 3 1.6
251-260 2 1.1
missing 28
213 100
Mean = 155.6
SD = 32.2
N = 185
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Table 6
Weight at twelve months for all subjects
WEIGHT IN POUNDS FREQUENCY PERCENT
<100 3 1.6
100 - 110 6 3.1
111 - 120 15 7.7
121 - 130 21 10 . 9
131 - 140 28 14.5
141 - 150 35 18.2
151 - 160 19 9.8
161 - 170 14 7.3
171 - 180 24 12.4
181 - 190 12 6.2
191 - 200 1 .5
201 - 210 3 1.6
211 - 220 4 2.1
221 - 230 0 0
231 - 240 4 2.0
241 - 250 3 2.1
251 - 260 0 0
missing 20
213 100
Mean = 153.2
SD = 31.0
N = 193
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Table 7
Weight at twenty-four months for all subjects
WEIGHT IN POUNDS FREQUENCY PERCENT
<100 1 0 . 7
100-110 5 3.4
111-120 11 7.5
121-130 13 8.9
131-140 18 12 .4
141-150 19 13.0
151-160 26 17.8
161-170 16 11. 0
171-180 10 6.8
181-190 11 7.5
191-200 5 3.5
201-210 4 2.7
211-220 0 . 0
221-230 1 . 7
231-240 4 2.7
241-250 2 1.4
251-260 0 .0
missing 67
213 100
Mean = 154.7
SD = 30.3
N = 146
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DATA INFORMATION SHEET
ID # ____ MD   Stage _____
Year Dx ______ Date therapy started_______
Date therapy ended _____
Drugs used Tamoxifen ___ Megace   Prednisone ___
Doxorubicin ___  Cytoxan   Methotrexate
5-Flurouracil ___
Year of birth _____
Race Black ___ White ___  Oriental   Spanish____
Native American ___
Treatment Radiation ___  Chemotherapy   Hormonal
Surgery ___
Type of surgery Modified Radical ___
Lumpectomy w Axillary node dissection ___
Radical Mastectomy ___ Simple Mastectomy
Pregnancy Y ___ N ___  number______
Age at first pregnancy _____
Family History of breast cancer Y N
Sisters ___ Mother ___  Daughters____
Grandmother ___ Aunt____
Number of positive axillary nodes ____
85
Breast Location Size in cm.
Left Upper Outer
Right Upper Inner
Both Lower Outer
Lower Inner
Dose of XRT ________________  Rads
Receptor status ER+ ___ ER- ___ PR+   PR-
Menopausal status Pre ___ Post ___ Peri____
DNA ploidy _______  S phase ______
Recurrent disease Y ___ N ___
Treatment ___________________________________
Ht.
Wt. initial ____
Three months ____
Six months ____
Nine months _____
Twelve months _____
Eighteen months ___
Twenty-four months
Secondary Diagnosis
86
APPENDIX D
LETTERS OF PERMISSION
HEATHER J. ALLEN, M.D., LTD.
Oncology and Hematology 
3006 S. Maryland Parkway, Suite 205, las Vegas, Nevada 89109
(702) 735-4002
7 September 1992
To whom it may concern:
Sheryl Therrien, a graduate student at University of Nevada Las Vegas, has my permission to 
review the charts of breast cancer patients in my office for the purpose of collecting data for her 
master's thesis. I understand that the data does not include any idetifying data and that patient 
confidentiallity will therefore be maintained. I understand that Sheryl is looking at a relationship 
between breast cancer diagnosis and weight gain.
Sincerely,
• - i
ARNOLD WAX,, M.D.
.
BOARD C E R T I F I E D  INTERNAL M E D J C W E  
BOARD CERTIFIED M EDICAL O N C O L O G Y
( 7 0 F ) * ( W  *001 
Until* PR  A r p n ln lw e n l O n l y
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i■I
• I
1 7 September 1992
To wliom it may concern:
■' j  Sheryl Thcrricn, a graduate student at University o f Nevada Las Vegas, ImS my permission lo 
■ 'Vil review the cliarts o f breast cancer patients in my office for the purpose of collecting data for her 
, ( master's thesis. I understand that the data docs not Include any idclliying data and that pntieid 
• ' '  ! conGdcntiallily will therefore be maintained. 1 understand lliat Sheryl is looking nt a iclntlonsliip 
; between breast cancer diagnosis and weight gain.
I
I •
Sincerely
i
I. , 
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•'I
i
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Permission to Use Copyrighted Material
, holder of copyright on material
entitled
authored by
and originally published in
________________________________________________________, hereby
give permission for the author to use the above-described material 
in total or in part for inclusion in a master's thesis/doctoral 
dissertation at the University of Nevada, Las Vegas.
I also agree that the author may execute the standard contract with 
University Microfilms International for microform reproduction of 
the completed thesis/dissertation, including the materials to which 
I hold copyright.
Signature:
Date: ____________
Name (typed): A/^f *
Title: X// ■ /^ / f)
Representing: ______________
The Graduate College 
University of Nevada, Las Vegas 
4505 Maryland Parkway 
Las Vegas, Nevada 89154
RECEIVED 
O C T  2 1S32
Ii:- ' ' I M E  COLLEG E
10 September 1992
Sheryl Therrien
2039 Civic Center Drive # 157
North Las Vegas, Nevada
Betty Neuman, Ph.D.
Box 488 
Beverly, Ohio
Dear Sirs,
I am a graduate student at the University of Nevada Las Vegas. I am currently in the process of writing 
my thesis for completion of a master's in science, nursing. 1 am using your Model to guide my thesis 
project on weight gain in breast cancer. In writing the rationale for using your model I find I need to 
reproduce the diagram of the model in my appendices. I am writing you to request your permission to 
reproduce the model from your publication: The Neuman Systems Model (second edition), 26, figure 1-3. 
I thank you for you consideration of this request and look forward to an answer soon. If I can answer any 
questions or expedite this permission in any way please let me know.
I wrote to Appleton and Lange first and their reply was that they could not give me permission to use the 
diagram as you own the copyright. Thank you in advance for your consideration of my request. I look 
forward to hearing from you.
Again thank you for you help and time.
Sheryl Therrien
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SUBMIT TO OFFICE OF THE GRADUATE DEAN: Original and
11 copies of the Protocol Form (pp. 1-3) plus one 
copy of the entire research proposal.
APPENDIX C 
DATE RECEIVED:
UNIVERSITY OF NEVADA, LAS VEGAS 
PROTOCOL FORM 
FOR RESEARCH INVOLVING HUMAN SUBJECTS
INVESTIGATORS: List person principally responsible for 
the investigation on line a). If principal investigator 
is a student, list faculty advisor on line b).
LOG 4
Investigator Department
TYPE OF REVIEW 
( ) Expedited 
( ) Regular
FUNDING SOURCE: 
( ) University 
( ) State 
( ) Federal 
Other/None
Phone
Sheryl Therrien, RN 
c'Margaret Louis, Ph.D.
d)
UNLV status of Principal Investigator (circle): Faculty/Post-<3octoral^raduate
/Undergraduate/Other____
TITLE OF PROJECT .height Gain in Woman-With Breast-Ganeer—  -----------
NAME AND ADDRESS of sponsoring agency or foundation (if other than UNLV)_
None _______
CONTRACT OR GRANT NUMBER (if known) None____________________________
DURATION OF STUDY (Protocols must be renewed annually) 9/92 Start i?/cgonclude
TYPE OF SUBMISSION XX New
Continuation
Renewal (attach progress report) 
"Modification 
"Previous Log I (if any)
LOCATION(S) OR FACILITIES where study will take place Heather Allen, MD and Arnold 
Wax, MD office, 3006 S. Maryland Parkway, Las Vegas, Nevada.
Date
25 September 1992
iho Princi Investigator's Signature
Date
/Q.-<2.01 9. cL
/6 -<£c> ~ <?'£
Date
/ 2 l £ m
De'i^ rtment Cha 
Signature
m
CML-nit Head's
Advisor's Signature 
warranted)
94
SUBJECTS: (Please estimate numbers.)
  Patients as experimental subjects
  Patients as controls
  Minors (under 18)
  tINLV Students
  Pregnant women or fetuses
  Mentally disabled
Prisoners, incarcerated 
subjects
Normal adult volunteers
Persons whose first 
language is not 
English.
XXX Other (please specify) 
MedicalRecords 200
200 TOTAL ANTICIPATED SUBJECTS
PROCEDURES: (ATTACH relevant materials, such as questionnaires, interview
schedules, written test instruments, etc.)
xxx
Survey, questionnaire(s) 
Interview: phone/in-perscn 
Medical or other personal records 
Filming, taping, recording 
Observation
Participant observation 
Anthropological fieldwork 
Psychological intervention 
Incomplete disclosure of purpose 
Payment of subjects 
Costs to subjects/third parties 
Brief Explanation of Procedures:
Investigational Drug*
Approved Drug, New Use*
Investigational Device 
(Attach relevant info.)
Placebo
Ionizing Radiation 
(Attach CURRENT approval)
Surgery
In vitro fertilization
Venipuncture
Other body fluids, 
excreta
Abortus, placenta, excess 
tissue
Other (please specify)
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UNIVERSITY OF NEVADA, LAS VEGAS 
PROTOCOL FORM APPROVAL SHEET 
FOR RESEARCH INVOLVING HUMAN SUBJECTS
Ixjj* Number:_________________________
Title of Project: g n  in m  6dOw\M OJ / 4J\ breeds-/ f
invcstigator: '^ t ! ? Tr/<?/)__________________________________
After reviewing this proposal, the members of the ___________________________
Review Committee have indicated below their approval/disapproval of this proposal.
Signature of Committee Members /) Approye^ Disapprove
______
 S U a  a ) zi t
The above named project is herelj^ approved/disapproved (circle one) 
Hate:
>v ^
Committee /Chairman1 s Signature
ASSOCIATE VICE PRESIDENT FOR RESEARCH
UNIVERSITY OF NEVADA, LAS VEGAS 
450 5  MARYLAND PARKWAY • LAS VEGAS, NEVADA 89154-1002  » (702) 597-4240  • FAX (702) 597-4242
TO: Sheryl Therrien
FROM: Dr. William E. Schulze, Director, Research Administration
DATE: November 4, 1992
RE: Status of human subject protocol entitled:
"Weight Gain in Women with Breast Cancer"
The protocol for the project referenced above has been reviewed by the Office of Research 
Administration, and it has been determined that it meets the criteria for exemption from full 
review by the UNLV human subjects committee. Except for any required conditions or 
modifications noted below, this protocol is approved for a period of one year from the date of 
this notification, and work on the project may proceed.
Should the use of human subjects described in this protocol continue beyond one year from the 
date of this notification, it will be necessary to request an extension.
If you have any questions or require any assistance, please give us a call.
According to Nevada revised statutes health care records are 
the property of the physician or agency caring for the 
client and the have the right to allow inspection of the 
charts for statistical and study purposes providing client 
confidentiality and privacy are maintained.
NRS 629.051 Health care records: Retention. Each provider 
of health care shall retain the health care records of his 
patients as part of his regularly maintained records for 
five years after their receipt or production. Health care 
records may be retained by microfilm or any other recognized 
form of size reduction which does not adversely affect their 
use for the purposes of NRS 629.061.
NRS 629.061 Health care records: Inspection; use in public 
hearing; immunity of certain persons from civil action for 
disclosure.
1. Each provider of health care shall make the health 
care records of a patient available for physical inspection 
by:
a. The patient or a representative with written 
authorization from the patient;
b. An investigator for the attorney general or a 
grand jury investigating an alleged violation of NRS 422.540 
to 433.570 inclusive; or
c. Any authorized representative or investigator 
of a state licensing board during the course of any 
investigation authorized by law.
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The records must be made available at a place within the 
depository convenient for physical inspection, and 
inspection must be permitted at all reasonable office hours 
and for a reasonable length of time. The provider of health 
care shall also furnish a copy of the records to each person 
described in paragraphs a and c of this subsection who 
requests it and pays the actual cost of postage, if any, the 
costs of making the copy, not to exceed sixty cents per page 
for photocopies and a reasonable cost for copies of x-ray 
photographs and other health and care records produced by 
similar processes. No administrative fee or additional 
service fee of any kind may be charged for furnishing such a 
copy.
2. Each person who owns or operates an ambulance in 
this state shall make his records regarding a sick or 
injured patient available for physical inspection by:
a. The patient or a representative with written 
authorization from the patient; or
b. Any authorized representative or investigator 
of a state licensing board during the course of any 
investigation authorized by law.
The records must be made available at a place within the 
depository convenient for physical inspection, and 
inspection must be permitted at all reasonable office hours 
and for a reasonable length of time. The person who owns or 
operates an ambulance shall also furnish a copy of the 
records to each person described in paragraphs a and b of
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this subsection who requests it and pays the actual cost of 
postage, if any, and the costs of making the copy, not to 
exceed sixty cents per page for photocopies. No 
Administrative fee or additional service fee of any kind may 
be charged for furnishing a copy of the records.
3. Records made available to a representative or 
investigator must not be used at any public hearing unless:
a. The patient named in the records has consented 
in writing to their use; or
b. Appropriate procedures are utilized to protect
the identity of the patient from public disclosure.
This subsection does not prohibit a state licensing board 
from providing to a provider of health care or owned or 
operator of an ambulance against whom a complaint or written 
allegation has been filed, or to his attorney, information 
on the identity of a patient whose records may be used in a 
public hearing relating to the complaint or allegation, but 
the provider of health care or owner or operator of an
ambulance shall keep the information confidential.
4. A provider of health care or owner or operator of an 
ambulance, his agents and employees are immune from any 
civil action for any disclosures made in accordance of this 
section or any consequential damages.
NRS 630.254 Active Licensees: Report of change of location 
or close of office; location of records.
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1. Any licensee who changes the location of his office 
shall notify the board of the change before practicing at 
the new location.
2. Any licensee who closes his office shall:
a. Notify the board of this occurrence within 
fourteen days after the closure; and
b. For a period of five years thereafter keep the 
board apprised of the location of the medical records of his 
patients.
NRS 457.230 Establishment and maintenance of system for 
reporting information; objectives.
1. The state health officer shall, pursuant to 
regulations of the state board of health, establish and 
maintain a system for the reporting of information on 
cancer.
2. The system must include a record of the cases of 
cancer which occur in this state along with such information 
concerning the cases as may be appropriate to form the basis 
for:
a. Conduct of comprehensive epidemiologic surveys 
of cancer and cancer related diseases in the state; and
b. Evaluation of the appropriateness of measures 
for prevention and control of cancer.
APPENDIX G
T,N,M STAGING METHOD
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T,N,M, Staging
T Primary tumors
Ti Tumor 2 cm. or less in its greatest dimension
a. No fixation to underlying pectoral fascia
or muscle
b. Fixation to underlying pectoral fascia or 
muscle
T2 Tumor more than 2 cm. but not more than 5 cm. in its 
greatest dimension
T3 Tumor more than 5 cm. in its greatest dimension
a. No fixation to underlying pectoral fascia 
or muscle
b. Fixation to underlying pectoral fascia or 
muscle
T4 Tumor of any size with direct extension to chest wall 
or skin
a. Fixation to chest wall
b. Edema, ulceration of the skin of the
breast, or satellite skin nodules confined 
to the same breast
c. Both of above
d. Inflammatory carcinoma
N Regional lymph nodes
NO No palpable homolateral axillary nodes
N1 Movable homolateral axillary nodes
a. Nodes not considered to contain growth
b. Nodes considered to contain growth
N2 Homolateral axillary nodes containing growth and fixed 
to one another or to other structures
N3 Homolateral supraclavicular or infraclavicular nodes 
containing growth or edema of the arm
M Distant metastases
MO No evidence of distant metastases
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Ml Distant metastases present, including skin 
involvement beyond breast area
Stage I Tia or Tib NO or Nia MO
Stage II TO Nib MO
Tla or Tib Nib MO
T2a or T2b NO, Nla or Nib MO
Stage III Tla or Tib N2 MO
T2a or T2b N2 MO
T3a or T3b NO, Ni or N2 MO
Stage IV T4 any N any M
any T N3 any M
any T any N Ml
Approved by both the International Union against cancer and 
the American joint commission on cancer staging and end 
reports.
